skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Adenosine A2a receptor agonists as regulators of inflammation: pharmacology and therapeutic opportunities

Review

(3893) Views  (1583) Full article downloads

Authors: Silvana Morello, Rosalinda Sorrentino, Aldo Pinto

Published Date August 2009 Volume 2009:2 Pages 11 - 17
DOI: http://dx.doi.org/10.2147/JRLCR.S4710

Silvana Morello, Rosalinda Sorrentino, Aldo Pinto

Department of Pharmaceutical Sciences, Biomedical Section, University of Salerno, Via Ponte don Melillo, 84084 Fisciano, Salerno, Italy

Abstract: A2a receptor (A2aR) plays an important role in the regulation of inflammatory and immune responses. The activation of PKA-dependent and/or -independent pathways are responsible for the downmodulation of inflammatory networks and tissue injury. Based on promising recent studies, selective A2aR agonists are under clinical investigations for a wide range of disorders, such as ischemia-reperfusion injury, chronic inflammation, and infectious diseases. Nevertheless, further studies are required to improve our understanding in the ability of A2a receptor agonists to reduce tissue damage during inflammation. Characterization of A2aR-induced signaling pathways will be useful for the development of novel therapeutic strategies in inflammatory/immune diseases.

Keywords: adenosine, A2a receptor, A2a receptor agonists, inflammation








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Hematocrit and mean arterial blood pressure in pre- and postmenopause women
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
An improved delivery system for bladder irrigation
The RT-18: a new screening tool to assess young adult risk-taking behavior
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
The use of dopamine-hyaluronate associate-coated maghemite nanoparticles to label cells